1[1]Meijden A P, Hall R R, Macaluso M P, et al. Marker tumor response to the sequential combination of intravesical therapy with mitomycin-c and BCG-RIVM in multiple superficial bladder tumors. Eur urol, 1996, 29:199-205.
2[2]Badalament R A, Frandlin G L, Page C M, et al. Enhencement of bacillns calmette-Guerin attachment to the urothelium by removal of the rabbit bladder mucin layer. J Urol , 1992, 147:482-486.
3[3]Zrol A, Ozgur S, Basar M.Trial with bacillus calmette-Guerin and epriubicin combination inthe prophylaxis of superficial bladder cancer. Urol Int, 1994, 52:69-74.
5Toma C,John MF.Bladder cancer[M].In Robert JS,Mike BS,John MF,eds.Clinical Urology.JB Lippncott Company Philadephia,1994:637-44.
6Belldegrun AS,Franklin JR,O'Donnell MA,et al.Superficial bladder cancer:the role of interferon-α[M].J Urol,1998,159:1793-801.
7Sekine H,Fukui I,Yamada T,et al.Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder:A longer followup result[J].J Urol,1994,151:27-30.
8Seraphim LA,Perrapato SD,Slocum HR.In vitro study of the interaction of doxorubicin,thiotepa and mitomycin C agents used for intravesical chemotherapy of superficial bladder cancer[J].J Urol,1991,145:613-7.
9Okamoto E,Kinne R.K.H,Sokeland J.Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C[J].J Urol,1996,156:1492-5.
10Uekado Y,Hirano A,Shinka T,et al.The effects of intravesical chemoimmunotherapy with epirubicin and bacillus calmette-guerin for prophylaxis of recurrence of superficial bladder cancer:a preliminary report[J].Cancer Chemother Pharmacol,1994,35:65-8.
